Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zedoresertib + Temozolomide +/- Radiotherapy in Glioblastoma
NCT05765812Phase 2Recruiting
- Sponsor
- Debiopharm
- Start
- May 2023
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of zedoresertib in glioblastoma (GBM), astrocytoma, sponsored by Debiopharm. Started May 2023; status: recruiting.
02
Drugs
zedoresertib
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on NCT05765812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05765812.